^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    FAT3 (FAT Atypical Cadherin 3)

    i
    Other names: FAT3, FAT Atypical Cadherin 3, CDHF15, Cadherin-Related Family Member 10, FAT Tumor Suppressor Homolog 3, Cadherin Family Member 15, Protocadherin Fat 3, KIAA1989, CDHR10, HFat3, FAT Tumor Suppressor Homolog 3 (Drosophila)
    1m
    Molecular profiling of hepatoid adenocarcinoma and adenocarcinoma with enteroblastic differentiation. (PubMed, Surg Oncol)
    HAD/ACED demonstrated higher TP53 mutation accumulation and TP53-related cancer stemness gene overexpression, including LIN28B, IGF2BP1, and HMGA2. Therefore, TP53 and these cancer stemness genes might be involved in the occurrence of HAD/ACED.
    Journal
    |
    TP53 (Tumor protein P53) • LRP1B (LDL Receptor Related Protein 1B) • CREBBP (CREB binding protein) • AFP (Alpha-fetoprotein) • GPC3 (Glypican 3) • FAT3 (FAT Atypical Cadherin 3) • HMGA2 (High mobility group AT-hook 2) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • SALL4 (Spalt Like Transcription Factor 4) • APOB (Apolipoprotein B) • CSMD3 (CUB And Sushi Multiple Domains 3) • LIN28B (Lin-28 Homolog B)
    |
    TP53 mutation
    2ms
    Recent advances in the study of FAT family genes in lung cancer. (PubMed, Discov Oncol)
    This study comprehensively integrated and analyzed research results on the characteristics of the FAT gene family in lung cancer, focusing on its mutations, signaling pathways, and immunological roles, as well as its clinical significance in terms of prognosis. This study provides theoretical support and references for the development of targeted therapeutic strategies.
    Review • Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CDH1 (Cadherin 1) • FAT1 (FAT atypical cadherin 1) • FAT3 (FAT Atypical Cadherin 3) • FAT4 (FAT Atypical Cadherin 4) • TGFB1 (Transforming Growth Factor Beta 1) • FAT2 (FAT Atypical Cadherin 2)
    5ms
    Therapeutic targeting of triple-negative breast cancer: A multi-model evaluation of LNA-anti-miR-19b-3p and small molecule inhibitors. (PubMed, Comput Biol Med)
    Additionally, we screened for potential small molecule inhibitors, identifying four promising candidates, including Dovitinib, S-Adenosylmethionine, Guanosine-5',3'-tetraphosphate, and Neomycin, which exhibited favorable drug-like characteristics. In conclusion, our multifaceted approach demonstrates the significant potential of LNA-anti-miR-19b-3p as a therapeutic option for TNBC patients, and the small molecule inhibitors we've uncovered could open new avenues for treating this aggressive form of breast cancer.
    Journal
    |
    FAT3 (FAT Atypical Cadherin 3) • MIR19B1 (MicroRNA 19b-1) • ANXA5 (Annexin A5)
    |
    dovitinib (TKI258)
    7ms
    Novel germline and somatic variants in familial and sporadic meningioma genes. (PubMed, NPJ Genom Med)
    Chromosomal abnormalities were identified in 39 of 49 tumors that also carried germline or somatic variants, with 71.8% encompassing NF2. This study provides potential novel genetic risk factors of meningiomas appropriate for further exploration from the greater scientific community and pathways to consider in the design of future therapeutic approaches.
    Journal
    |
    FAT3 (FAT Atypical Cadherin 3) • CSMD3 (CUB And Sushi Multiple Domains 3) • RECQL4( RecQ Like Helicase 4)
    11ms
    Longitudinal genomic profiling using liquid biopsies in metastatic nonsquamous NSCLC following first line immunotherapy. (PubMed, NPJ Precis Oncol)
    STK11, SMARCA4, KRAS, SLT2, and KEAP1 mutations showed the strongest correlation with poorer overall survival, while SMARCA4, STK11, SPTA1, TBX3, and KEAP1 mutations correlated with shorter progression-free survival. Overall, longitudinal liquid biopsy profiling provided valuable insights into lung cancer biology post-immunotherapy, potentially guiding personalized therapies and future drug development.
    Journal • Liquid biopsy • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1) • LRP1B (LDL Receptor Related Protein 1B) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • KMT2C (Lysine Methyltransferase 2C) • FAT3 (FAT Atypical Cadherin 3) • SPTA1 (Spectrin Alpha) • CDH2 (Cadherin 2) • SFTPA1 (Surfactant Protein A1)
    |
    TP53 mutation • KRAS mutation • STK11 mutation • KEAP1 mutation
    1year
    Aggressive high-grade NF2 mutant meningiomas downregulate oncogenic YAP signaling via the upregulation of VGLL4 and FAT3/4. (PubMed, Neurooncol Adv)
    In vitro, overexpression of VGLL4 resulted in the downregulation of YAP activity in benign NF2 mutant meningioma cells, confirming the direct link between VGLL4 expression and decreased levels of YAP activity observed in aggressive NF2 mutant meningiomas. Our results shed new insight into the biology of benign and aggressive NF2 mutant meningiomas and may have important implications for the efficacy of therapies targeting oncogenic YAP1 activity in NF2 mutant meningiomas.
    Journal
    |
    NF2 (Neurofibromin 2) • YAP1 (Yes associated protein 1) • FAT3 (FAT Atypical Cadherin 3) • VGLL4 (Vestigial Like Family Member 4)
    |
    NF2 mutation
    over1year
    Tumor mutation burden and FAT3 mutation influence long-term survival in surgically resected small cell lung cancer. (PubMed, Transl Lung Cancer Res)
    This study provides valuable information about the molecular differences between LTS and STS patients. Studies with larger sample sizes need to be conducted to confirm our findings in the future.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • FAT3 (FAT Atypical Cadherin 3)
    over1year
    Novel genetic alterations in liver cancer distinguish distinct clinical outcomes and combination immunotherapy responses. (PubMed, Front Pharmacol)
    Comprehensive genomic profiling deciphered distinct molecular characterizations underlying VI, location of onset, recurrence, and survival time in liver cancer. The identification of novel genetic predictors of response to anti-PD-1 plus bevacizumab in HCC facilitated the development of an evidence-based approach to therapy.
    Clinical data • Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • RB1 (RB Transcriptional Corepressor 1) • BAP1 (BRCA1 Associated Protein 1) • KMT2D (Lysine Methyltransferase 2D) • MSH2 (MutS Homolog 2) • KMT2C (Lysine Methyltransferase 2C) • FAT1 (FAT atypical cadherin 1) • NOTCH3 (Notch Receptor 3) • FAT3 (FAT Atypical Cadherin 3) • ZFHX3 (Zinc Finger Homeobox 3) • KDM5D (Lysine Demethylase 5D) • PDE4DIP (Phosphodiesterase 4D Interacting Protein) • LATS1 (Large Tumor Suppressor Kinase 1) • PDE3A (Phosphodiesterase 3A) • SYNE1 (Spectrin Repeat Containing Nuclear Envelope Protein 1) • MYO18A (Myosin XVIIIA) • PTPRZ1 (Protein Tyrosine Phosphatase Receptor Type Z1)
    |
    Avastin (bevacizumab)
    over1year
    Half of most frequently mutated genes in breast cancer are expressed differentially between premenopausal and postmenopausal breast cancer patients. (PubMed, Cancer Genet)
    Unlike what we observed in the case of ER or PR status, the expression of most of these genes does not change depending on HER2 (human epidermal growth factor receptor 2) status in both premenopausal and postmenopausal breast cancer patients. Combined, our analysis suggests that menopause status might influence the expression of most frequently mutated genes in breast cancer, and that the most of these genes whose expression differ between pre- and post-menopausal women with breast cancer also show ER or PR status-dependent expression in women with breast cancer.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • PTEN (Phosphatase and tensin homolog) • ARID1A (AT-rich interaction domain 1A) • RUNX1 (RUNX Family Transcription Factor 1) • LRP1B (LDL Receptor Related Protein 1B) • CDH1 (Cadherin 1) • MUC16 (Mucin 16, Cell Surface Associated) • FAT1 (FAT atypical cadherin 1) • FAT3 (FAT Atypical Cadherin 3)
    over1year
    Aggressive high-grade NF2 mutant meningiomas downregulate oncogenic YAP signaling via the upregulation of VGLL4 and FAT3/4. (PubMed, bioRxiv)
    In vitro, overexpression of VGLL4 resulted in the downregulation of YAP activity in benign NF2 mutant meningioma cells, confirming the direct link between VGLL4 expression and decreased levels of YAP activity observed in aggressive NF2 mutant meningiomas. Our results shed new insight on the biology of benign and aggressive NF2 mutant meningiomas and may have important implications for the efficacy of therapies targeting oncogenic YAP1 activity in NF2 mutant meningiomas.
    Journal
    |
    NF2 (Neurofibromin 2) • YAP1 (Yes associated protein 1) • FAT3 (FAT Atypical Cadherin 3) • VGLL4 (Vestigial Like Family Member 4)
    over1year
    Antitumor immunity and prognosis value elicited by FAT3 and LRP1B co-mutation in endometrial cancer. (PubMed, Gynecol Oncol)
    In endometrial cancer, co-mutation of FAT3 and LRP1B not only leads to activation of the immune state, but also represents a subgroup with an improved prognosis, particularly in the MSI-H subtype.
    Journal • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • LRP1B (LDL Receptor Related Protein 1B) • FAT3 (FAT Atypical Cadherin 3)
    |
    MSI-H/dMMR • LRP1B mutation • FAT3 mutation
    over1year
    Identification of nomogram associated with durable clinical benefit gene for advanced non-small cell lung cancer with sensitivity to responsive to immunotherapy. (PubMed, Heliyon)
    Our study revealed that PGR, PTPRD, RELN, MUC19, LRP1B, and FAT3 mutation could serve as predictive biomarkers. Our systematic nomograms demonstrate significant potential in predicting the prognosis for NSCLC patients with sensitivity to different ICI treatment strategies.
    Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    TP53 (Tumor protein P53) • LRP1B (LDL Receptor Related Protein 1B) • FAT3 (FAT Atypical Cadherin 3) • PTPRT (Protein tyrosine phosphatase receptor type T) • MUC19 (Mucin 19, Oligomeric)
    |
    TP53 mutation • FAT3 mutation